Tissue Regenix Group plc
TSSNF
Other OTC0.01
USD
- -
- -
Return %
Stock
S&P500
1Y
- -
26.53
3Y
- -
76.60
5Y
- -
80.11
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- CEO
- Daniel R. Lee
- Full Time Employees
- 79
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- Unit 3 Garforth United Kingdom LS25 2GY
- IPO Date
- Nov 14, 2016
- Website
- tissueregenix.com
- Similar Companies
- Business
- Tissue Regenix Group plc is an international medical technology company specializing in regenerative medicine, developing and commercializing platform technologies for bone graft substitutes, skin, and soft tissue regeneration. The company’s core products are built on two proprietary platform technologies: dCELL®, which addresses soft tissue needs by decellularizing animal and human tissues to create acellular tissue scaffolds for implantation, and BioRinse™, which provides sterile bone allografts designed to promote new bone growth and faster healing. Notable products include DermaPure® for soft tissue repair, OrthoPure XT for sports medicine applications, ConCelltrate® for orthopedic and dental uses, and AmnioWorks™ for ophthalmology and wound care. These products serve clinical areas such as biosurgery, orthopedics (sports medicine and spine), dental, general surgery, plastic surgery, urology/gynaecology, ophthalmology, and cardiac surgery. The company operates globally with main facilities in Leeds, UK; San Antonio, Texas, USA; and Rostock, Germany. Founded in 2006 and headquartered in Leeds, United Kingdom, Tissue Regenix has recently expanded its product portfolio and commercial footprint. A key strategic development was the 2017 acquisition of CellRight Technologies, a US-based company specializing in regenerative osteoinductive bone scaffolds, which enhanced Tissue Regenix’s presence in the US healthcare market and expanded its regenerative medicine product offerings. In 2023 and 2024, the company launched new product lines for sports medicine and soft tissue, including DermaPure® Mesh and VNEW® M for pelvic organ prolapse repair, backed by new processing protocols to improve product sterility and performance. Tissue Regenix also reported strong sales growth in its BioRinse® product line in the US market and a commercial reorganization of its dCELL® division resulted in 17% sales growth in 2023. The company continues to expand its distribution network with over 66 new distributors added in 2023, reinforcing its strategic partnerships and market penetration. Tissue Regenix recorded group revenues of approximately $28.6 million in FY 2024, driven by increased donor tissue processing capacity and enhanced operational efficiencies. Its products are distributed through a combination of direct specialist sales, strategic partners, and private label arrangements. The company aims to lead innovation in regenerative medicine by continuously enhancing its product offerings and expanding its geographic and market reach in the surgical applications it serves. Tissue Regenix's business model leverages cutting-edge tissue engineering technologies to support natural tissue regeneration and improved clinical outcomes for patients worldwide.